**给予患者伊马替尼600mg/d，持续4周；若观察到SD或PR，则将继续另外4周的治疗；此时患者可进行肿瘤切除手术；恢复2-4周后，给予患者伊马替尼600mg/d，持续服用2年。不能反映新辅助治疗全组的疗效,无对照组,无法评估新辅助治疗是否优于直接手术.RadiationTherapyOncologyGroup.RTOGS-0132:aphaseIItrialofneoadjuvant/adjuvantSTI-571(GleevecNSC#716051)forprimaryandrecurrentoperablemalignantGISTexpressingtheKITreceptortyrosinehinase(CD117).Availableat:/members/protocols/S0132/S0132.pdf.AccessedJuly2004.**该研究的主要目的是评价患者接受肿瘤切除后伊马替尼治疗对PFS的影响；次要目的：评价伊马替尼在新辅助治疗中疾病的缓解率比较新辅助治疗中通过PET和CT检查反映疾病缓解的情况新辅助治疗的安全性给予患者伊马替尼每天600mg；必须是源自内脏、腹腔内或盆腔的原发性肿瘤。RadiationTherapyOncologyGroup.RTOGS-0132:aphaseIItrialofneoadjuvant/adjuvantSTI-571(GleevecNSC#716051)forprimaryandrecurrentoperablemalignantGISTexpressingtheKITreceptortyrosinehinase(CD117).Availableat:/members/protocols/S0132/S0132.pdf.AccessedJuly2004.TheSSGXVIII/AIOtrialevaluatedadjuvantimatinibfor12or36monthsinpatientswithKIT-positiveGISTathighriskforrecurrenceaftersurgery.SSGXVIIIisaprospective,open-label,multicenter,randomized,phase3study,wherethepatientswererandomizedina1:1ratiototreatmentwithimatinib400mgoncedailyorallyeitherfor12monthsorfor36monthsasadjuvanttreatmentofGISTfollowingsurgeryAtrandomization,patientswereclassifiedinto2strata:eitherR0resection(completesurgicalremovalofthetumor)orR1surgery(suspectedmicroscopicalresidualtumorinfiltrationortumorrupture)ThetrialstartedinFebruary2004andcompleteditstargetedenrollmentof400patients(200patientseachgroup)inSeptember2009JoensuuH,ErikssonM,HatrmannJ,etal.Twelveversus36monthsofadjuvantimatinib(IM)astreatmentofoperableGISTwithahighriskofrecurrence:Finalresultsofarandomizedtrial(SSGXVIII/AIO).JClinOncol.2011;29(suppl).AbstractLBA1.**TheSSGXVIII/AIOtrialevaluatedadjuvantimatinibfor12or36monthsinpatientswithKIT-positiveGISTathighriskforrecu